Full-Time

Commercial Head

Iberia

Bimeda

Bimeda

1-10 employees

Global veterinary pharmaceuticals and animal health.

No salary listed

Barcelona, Spain

Hybrid

Based in Spain, with regular travel across Iberia and periodic travel to European sites.

Bachelor's

Category
Business & Strategy (1)
Required Skills
Sales
Forecasting
CRM
Financial analysis

Get referred to Bimeda

See people who can refer or advise you

Requirements
  • Strong understanding of veterinary and agricultural channels, including corporate groups, wholesalers, and integrators.
  • Direct experience in the Spanish and/or Portuguese animal health market, with an established network across veterinary corporate groups, buying groups, and distributors.
  • Knowledge of the livestock and equine production-animal sectors and a working understanding of the Spanish AEMPS and Portuguese DGAV veterinary medicines regulatory frameworks.
  • A proven track record in senior commercial or national sales roles dealing with large veterinary and trade customers.
  • Experience managing and developing high-performing commercial teams.
  • Demonstrated ability to shape and execute commercial strategy at country or regional level.
  • Strong financial acumen with the ability to interpret sales data, margin performance, and investment impact.
  • Strong contract negotiation skills, with experience structuring customer agreements, rebates, and trading terms, and a working understanding of the veterinary medicines regulatory environment.
  • A third-level qualification in a science, veterinary, agricultural, business, or commercial discipline.
  • Fluency in Spanish is essential and professional fluency in English is required for reporting and collaboration within the European and global organization.
Responsibilities
  • Build the Iberian strategy and organization for Bimeda’s entry into Spain and Portugal, then lead the regional commercial organization.
  • Build, lead, and develop a team of Key Account Managers and/or Territory Managers covering the Spanish and Portuguese markets.
  • Build capability in key account management and value-based selling.
  • Set clear objectives, coach performance, and create a high-performance culture based on accountability and customer focus.
  • Ensure compliance with relevant veterinary medicines regulations across both markets, working with Regulatory Affairs and the Responsible Person.
  • Build and own the local commercial strategy and define the long-term growth direction across species portfolios.
  • Identify and prioritize high-value opportunities, including new product launches, category expansion, shifts in customer behavior, and customer-group consolidation.
  • Ensure alignment with European and global business priorities.
  • Define and continuously review the route to market.
  • Act on market opportunities such as competitor out-of-stock situations, special import opportunities, and short-term supply gaps to capture volume and grow market share.
  • Monitor the competitive landscape, competitor pricing, and wider market trends to anticipate threats and identify new growth sources.
  • Oversee relationships with veterinary corporate groups, buying groups, wholesalers and distributors, and integrators.
  • Support Key Account Managers in developing joint business plans that deliver growth, category performance, and compliance.
  • Guide the team through complex price, volume, and contract negotiations.
  • Oversee customer contracts and trading agreements, ensuring terms are documented, commercially sound, and consistently applied.
  • Apply customer segmentation to focus on the highest-potential customers and products.
  • Drive revenue, margin, and market-share targets across Iberia.
  • Lead demand and sales forecasting, pipeline management, and performance analysis across product segments.
  • Ensure pricing, promotional execution, and investment decisions maximize profitability and return on investment.
  • Enable gross-to-net percentage evolution and customer-focused rebate-management programs, evolving the go-to-market model where required.
  • Ensure customer rebates, discounts, and promotional offers are monitored, accrued, and accounted for accurately.
  • Work with Finance to manage customer credit, debtor days, and working capital, and actively manage overdue accounts.
  • Work with Marketing, Technical, Regulatory, Supply Chain, and Finance teams to execute commercial plans.
  • Partner with technical and marketing teams to strengthen value propositions and customer outcomes.
  • Represent the Iberian markets in regional planning forums and provide market insight and commercial recommendations.
Desired Qualifications
  • A relevant postgraduate or commercial qualification is an advantage.
  • Working proficiency in Portuguese is a strong advantage.

Bimeda is a global veterinary pharmaceutical company that develops, manufactures, markets, and distributes animal health products. Its offerings range from medicines to wellness products for veterinarians, farmers, and animal health professionals, all aimed at improving animal health and wellbeing. The company supports its products with science from eight research and development laboratories, and distributes them in more than 80 countries. It grows through a mix of organic expansion and acquisitions, expanding its geographic reach and product lineup. A core focus is sustainability, integrating environmental and social responsibility into product development, delivery, and daily operations. Bimeda’s goal is to positively impact customers, communities, and the environment through collaboration, continuous improvement, and reliable animal health solutions.

Company Size

1-10

Company Stage

N/A

Total Funding

N/A

Headquarters

N/A

Founded

N/A

Get referred to Bimeda

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • GASTROBIM launched nationwide in May 2026, expanding Bimeda's fastest-growing omeprazole franchise.
  • Enhanced BOVitalize Plus debuted May 2026, strengthening cattle nutrition and performance sales.
  • Dr. Chris Olsen joined swine technical services, supporting autogenous vaccines and pharmaceuticals.

What critics are saying

  • GASTROBIM directly attacks Zoetis GastroGard, inviting immediate price compression in 2026.
  • Pomona integration creates execution risk, and Dechra supply handoffs can disrupt 2026 shipments.
  • If GASTROBIM stalls, Zoetis and Elanco keep Bimeda trapped in low-margin generics.

What makes Bimeda unique

  • Bimeda's April 2026 Pomona acquisition adds U.S. manufacturing capacity and supply control.
  • Its 2026 FDA-approved GASTROBIM matches GastroGard, targeting price-sensitive equine veterinarians.
  • Bimeda sells across 80 countries, pairing generic biosimilars with branded livestock support.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

Paid Vacation

Life Insurance

Employee Assistance Program

Paid Holidays

Company News

British Veterinary Association
Aug 4th, 2026
New treatment for bovine endometritis.

New treatment for bovine endometritis. 4 Aug 2026 11:00 AM Bimeda UK has launched Bimacure, which it says is the UK's first generic intrauterine cefapirin suspension for cattle, for the treatment of subacute and chronic endometritis. The formulation contains 500mg cefapirin per syringe and is for use in cows at least 14 days after parturition. It is supplied in packs of 10 sets each of syringes, administration catheters and gloves; the catheter and syringe connection have been designed to avoid 'pop offs' at critical moments. The firm says feedback about the product from other markets has been "extremely positive".

Feedstuffs
May 19th, 2026
Bimeda introduces enhanced BOVitalize Plus.

Bimeda introduces enhanced BOVitalize Plus. Product now fortified with A. oryzae to support cattle health, digestion and performance. May 19, 2026 Bimeda is proud to announce the launch of its newly enhanced BOVitalize Plus, now fortified with Aspergillus oryzae to deliver an even more comprehensive approach to cattle health, digestion and performance. This advancement builds on the trusted formulation of essential trace minerals and vitamins - selenium, copper, zinc, vitamin A and vitamin E - by adding targeted digestive support designed to help cattle get more from every bite of feed. For producers and veterinarians, the inclusion of A. oryzae represents a significant step forward in rumen efficiency. A oryzae provides enzymatic activity that enhances fiber breakdown, helping cattle maintain intake and digestive consistency during diet transitions, periods of stress or when forage quality declines. By supporting more efficient fiber utilization, the upgraded BOVitalize Plus helps optimize nutrient absorption, stabilize the rumen environment, and promote improved overall performance across all stages of production. This enhancement reflects its commitment to delivering solutions that truly support the challenges cattle face every day," said Dr. Eric Moore, head of technical services North America at Bimeda. "By combining key vitamins and minerals with the proven digestive benefits of Aspergillus oryzae - and refining how the formula performs in suspension - we're offering a more complete, performance-driven supplement designed to keep animals healthy, efficient and moving forward." The improved BOVitalize Plus continues to offer the same convenient oral dosing, eliminating the need for additional injections and reducing labor at the chute. With the added digestive benefits of A. oryzae, the product now delivers an even stronger value proposition for both cow-calf and stocker operations seeking to improve health, consistency and overall productivity. BOVitalize Plus is now available through authorized Bimeda distributors. Bimeda is a leading global manufacturer of animal health products used in more than 80 countries worldwide and is committed to providing innovative solutions that support livestock health, welfare and performance. Feedstuffs is the news source for animal agriculture

The Horse
May 6th, 2026
Bimeda(r) announces U.S. Availability of gastrobim(tm)(omeprazole) the first and only fda-approved bioequivalent to gastrogard(r)(omeprazole) for Equine Gastric Ulcer treatment.

Bimeda(r) announces U.S. Availability of gastrobim(tm)(omeprazole) the first and only fda-approved bioequivalent to gastrogard(r)(omeprazole) for Equine Gastric Ulcer treatment. Now available nationwide. Horse owners are encouraged to contact their veterinarian. Bimeda(R), a global leader in animal health solutions, today announced the U.S. launch of GASTROBIM(TM)(omeprazole), the first and only FDA-approved bioequivalent to GastroGard(R)(omeprazole) for the treatment and prevention of recurrence of gastric ulcers in horses and foals four weeks of age and older. This apple-flavored formulation offers veterinarians, trainers, and horse owners a clinically equivalent, high-quality alternative for the effective management of Equine Gastric Ulcer Syndrome (EGUS), addressing a critical need in equine health. Since its initial launch in 2024, GASTROBIM(TM) has rapidly emerged as the fastest-growing omeprazole product in Canada and Europe. Its strong adoption and positive reception among veterinarians and horse owners underscore its proven efficacy in treating and healing gastric ulcers, reinforcing its position as a trusted therapeutic option worldwide. The introduction of GASTROBIM(TM) in the U.S. further expands Bimeda's established equine portfolio, which includes leading brands such as EquiMAX(R)(1.87% ivermectin 14.03% praziquantel), Polyglycan(TM)(hyaluronic acid + chondroitin sulfates C4 & C6 + N-acetyl-D-glucosamine sterile solution), Detomequin(R)(detomidine hydrochloride), and Bimectin(R)(ivermectin paste), and reflects the company's ongoing commitment to delivering innovative, reliable solutions to the equine industry. "We are thrilled to introduce GASTROBIM(TM) to the U.S. market," said Eric Moore, DVM, Bimeda's Head of Technical Services North America. "Gastric ulcers remain one of the most common and performance limiting conditions in horses. Offering a bioequivalent, rigorously tested treatment underscores our commitment to supporting equine health, welfare, and performance at an affordable price." Equine Gastric Ulcer Syndrome (EGUS) affects a significant percentage of performance horses, often leading to reduced appetite, behavioral changes, discomfort, and decreased athletic performance. By introducing a bioequivalent, apple-flavored alternative, Bimeda aims to broaden access to effective treatment options and support improved health and performance outcomes across the equine industry.

American Association of Swine Veterinarians
Apr 15th, 2026
People on the move: dr. Chris Olsen.

People on the move: dr. Chris Olsen. Dr. Chris Olsen has joined Bimeda as their U.S. Swine Technical Service Veterinarian. In this role, he will support the growth of the company's swine autogenous vaccine business and provide technical expertise across its swine pharmaceutical portfolio. He was previously employed by Pharmacosmos. Dr. Olsen's updated contact information is available at aasv.org/directory. Are you on the move? Let Aasv Go know at [email protected].